Drugs Information: Enasidenib
Basic Information
|
||
| ID | DDInter639 | |
| Drug Type | small molecule | |
| Molecular Formula | C19H17F6N7O | |
| Molecular Weight | 473.381 | |
| Description | Enasidenib is an isocitrate dehydrogenase-2 inhibitor used to treat relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. | |
| ATC Classification | L01XX59 | |
| IUPAC Name | 2-Methyl-1-({4-[6-(Trifluoromethyl)Pyridin-2-Yl]-6-{[2-(Trifluoromethyl)Pyridin-4-Yl]Amino}-1,3,5-Triazin-2-Yl}Amino)Propan-2-Ol | |
| InChI | Inchi=1S/C19H17F6N7O/C1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/H3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32) | |
| InChI Key | DYLUUSLLRIQKOE-UHFFFAOYSA-N | |
| Canonical SMILES | CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C1=NC(=CC=C1)C(F)(F)F | |
| Useful Links | DrugBank ChEMBL PubChem | |
Interactions with Enasidenib
| Severity level | ID | Name | Mechanism | Detail |
|---|